(Q47328428)

14 January 2018

http://europepmc.org/abstract/MED/26839321

title

Betahistine decreases olanzapine-induced weight gain and somnolence in humans (English)

1 reference

14 January 2018

http://europepmc.org/abstract/MED/26839321

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26839321%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Yaffa Beck

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26839321%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Joseph H Albeck

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26839321%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

English

0 references

publication date

2 February 2016

1 reference

14 January 2018

http://europepmc.org/abstract/MED/26839321

published in

Journal of Psychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26839321%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26839321%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26839321%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

237-241

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26839321%20AND%20SRC:MED&resulttype=core&format=json

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Actions of betahistine at histamine receptors in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Betahistine: a retrospective synopsis of safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D₂ but not 5-HT2A/2C bindings in rat brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115626349

21 January 2018

Identifiers

DOI

10.1177/0269881115626349

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26839321%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference